Visudyne Related Published Studies
Well-designed clinical trials related to Visudyne (Verteporfin)
Improvement in multifocal electroretinography after half-dose verteporfin photodynamic therapy for central serous chorioretinopathy: a randomized placebo-controlled trial. [2011.07]
IMPROVEMENT IN MULTIFOCAL ELECTRORETINOGRAPHY AFTER HALF-DOSE VERTEPORFIN PHOTODYNAMIC THERAPY FOR CENTRAL SEROUS CHORIORETINOPATHY: A Randomized Placebo-Controlled Trial. [2011.03.03]
An observational retrospective subgroup analysis of verteporfin photodynamic therapy-naive and previously treated patients in the focus trial. [2011.01]
Verteporfin photodynamic therapy cohort study: report 3: cost effectiveness and lessons for future evaluations. [2009.12]
Verteporfin photodynamic therapy cohort study: report 2: clinical measures of vision and health-related quality of life. [2009.12]
Verteporfin photodynamic therapy cohort study: report 1: effectiveness and factors influencing outcomes. [2009.12]
Full macular translocation (FMT) versus photodynamic therapy (PDT) with verteporfin in the treatment of neovascular age-related macular degeneration: 2-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). [2009.06]
Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. [2009.01]
Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. [2008.10]
Half-Dose Verteporfin Photodynamic Therapy for Acute Central Serous Chorioretinopathy One-Year Results of a Randomized Controlled Trial. [2008.06.04]
Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. [2008.05]
Randomized multicenter trial of more intense and standard early verteporfin treatment of neovascular age-related macular degeneration. [2008.01]
Triamcinolone acetonide as adjunctive treatment to verteporfin in neovascular age-related macular degeneration: a prospective randomized trial. [2007.12]
Full macular translocation versus photodynamic therapy with verteporfin in the treatment of neovascular age-related macular degeneration: 1-year results of a prospective, controlled, randomised pilot trial (FMT-PDT). [2007.08]
Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. [2007.06]
Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study. [2006.11]
Ranibizumab versus verteporfin for neovascular age-related macular degeneration. [2006.10.05]
Comparison of early retreatment with the standard regimen in verteporfin therapy of neovascular age-related macular degeneration. [2005.12]
Effects of verteporfin therapy on central visual field function. [2004.05]
Photodynamic therapy of multiple nonmelanoma skin cancers with verteporfin and red light-emitting diodes: two-year results evaluating tumor response and cosmetic outcomes. [2004.01]
Treatment of choroidal neovascularization in central serous chorioretinopathy by photodynamic therapy with verteporfin. [2003.11]
Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. [2003.09]
Photodynamic therapy of subfoveal choroidal neovascularization with verteporfin: fluorescein angiographic guidelines for evaluation and treatment--TAP and VIP report No. 2. [2003.09]
Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. [2003.07]
Duration of skin photosensitivity and incidence of photosensitivity reactions after administration of verteporfin. [2002.12]
Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. [2002.11]
Effects of verteporfin therapy on contrast on sensitivity: Results From the Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) investigation-TAP report No 4. [2002.10]
Clinical pharmacokinetics of verteporfin. [2002.05]
Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. [2002.02]
Well-designed clinical trials possibly related to Visudyne (Verteporfin)
Assessment of differential pharmacodynamic effects using optical coherence
tomography in neovascular age-related macular degeneration. [2012]
Incidence of retinal pigment epithelial tears after intravitreal ranibizumab injection for neovascular age-related macular degeneration. [2011.12]
Anti-vascular endothelial growth factor for myopic choroidal neovascularization. [2011.09.08]
Patient characteristics and treatment of neovascular age-related macular degeneration in France: the LUEUR1 observational study. [2011.04]
Changes in macular sensitivity after reduced fluence photodynamic therapy combined with intravitreal triamcinolone. [2011.03]
A pilot study on the combination treatment of reduced-fluence photodynamic therapy, intravitreal ranibizumab, intravitreal dexamethasone and oral minocycline for neovascular age-related macular degeneration. [2011]
Incidence of retinal pigment epithelial tears after intravitreal ranibizumab
injection for neovascular age-related macular degeneration. [2011]
Changes in macular sensitivity after reduced fluence photodynamic therapy
combined with intravitreal triamcinolone. [2011]
Anatomical benefit from ranibizumab treatment of predominantly classic neovascular age-related macular degeneration in the 2-year anchor study. [2010.10]
A randomised prospective double-masked exploratory study comparing combination photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab monotherapy in the treatment of neovascular age-related macular degeneration. [2010.10]
Bevacizumab vs photodynamic therapy for choroidal neovascularization in multifocal choroiditis. [2010.09]
Bevacizumab for neovascular age related macular degeneration (ABC Trial): multicentre randomised double masked study. [2010.06.09]
Vision-related function after low-dose transpupillary thermotherapy versus photodynamic therapy for neovascular age-related macular degeneration. [2010.06]
Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. [2010.06]
Vision-related function after ranibizumab treatment by better- or worse-seeing eye: clinical trial results from MARINA and ANCHOR. [2010.04]
Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. [2010.04]
Low fluence rate photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. [2010.02]
Anatomical benefit from ranibizumab treatment of predominantly classic
neovascular age-related macular degeneration in the 2-year anchor study. [2010]
A randomised prospective double-masked exploratory study comparing combination
photodynamic treatment and intravitreal ranibizumab vs intravitreal ranibizumab
monotherapy in the treatment of neovascular age-related macular degeneration. [2010]
Photodynamic therapy and intravitreal triamcinolone for neovascular age-related macular degeneration: a randomized clinical trial. [2009.11]
Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. [2009.08]
Improved vision-related function after ranibizumab vs photodynamic therapy: a randomized clinical trial. [2009.01]
Time-dependent effects on contrast sensitivity, near and distance acuity: difference in functional parameters? (Prospective, randomized pilot trial of photodynamic therapy versus full macular translocation). [2008.05]
Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study. [2008.03]
Optical coherence tomography analysis of a randomized study combining photodynamic therapy with intravitreal triamcinolone. [2008.02]
Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results. [2007.12]
Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration. [2007.09]
Ranibizumab for the treatment of neovascular age-related macular degeneration: a review. [2007.09]
Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. [2006.12]
Topical gel vs subconjunctival lidocaine for intravitreous injection: a randomized clinical trial. [2006.11]
Twofold illumination photodynamic therapy scheme for subfoveal choroidal neovascularization in pathologic myopia: results from a randomized pilot study. [2006.09]
Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration. [2006.01]
Guidelines for interpreting retinal photographs and coding findings in the Submacular Surgery Trials (SST): SST report no. 8. [2005.04]
[Three-dimensional imaging of photodynamic effects and spontaneous course in choroidal neovascularization] [2004.07]
Proton therapy for exudative age-related macular degeneration: a randomized, sham-controlled clinical trial. [2002.12]
[Photodynamic therapy] [2002.09]
[Photodynamic therapy of subfoveal choroid neovascularization. Analysis of fixation behavior] [2002.08]
[Age-related macular degeneration--a public health problem] [2001.06]
Other research related to Visudyne (Verteporfin)
Ranibizumab, verteporfin photodynamic therapy or observation for the treatment of
myopic choroidal neovascularization: cost effectiveness in the UK. [2014]
Evaluation of verteporfin pharmakokinetics--redefining the need of
photosensitizers in ophthalmology. [2012]
EVEREST study: efficacy and safety of verteporfin photodynamic therapy in
combination with ranibizumab or alone versus ranibizumab monotherapy in patients
with symptomatic macular polypoidal choroidal vasculopathy. [2012]
Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up. [2011.08]
Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. [2011.04]
Resolution of bilateral corneal neovascularization and lipid keratopathy after photodynamic therapy with verteporfin. [2011.04]
A retrospective analysis of triple combination therapy with intravitreal bevacizumab, posterior sub-tenon's triamcinolone acetonide, and low-fluence verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration. [2011.03]
Photodynamic therapy with verteporfin combined with subconjunctival injection of bevacizumab for corneal neovascularization. [2011.01]
A long-term study of photodynamic therapy with verteporfin for choroidal neovascularization at the edge of chorioretinal atrophy in pathologic myopia. [2011]
Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration. [2011]
Improvement in multifocal electroretinography after half-dose verteporfin
photodynamic therapy for central serous chorioretinopathy: a randomized
placebo-controlled trial. [2011]
An observational retrospective subgroup analysis of verteporfin photodynamic
therapy-naive and previously treated patients in the focus trial. [2011]
Verteporfin photodynamic therapy of six eyes with retinal capillary haemangioma. [2010.12]
Acute severe visual decrease after photodynamic therapy with verteporfin: spectral-domain OCT features. [2010.11]
Fluorescein angiography-guided photodynamic therapy with half-dose verteporfin for chronic central serous chorioretinopathy. [2010.11]
Lucentis using Visudyne study: determining the threshold-dose fluence of verteporfin photodynamic therapy combined with intravitreal ranibizumab for exudative macular degeneration. [2010.10.05]
AN OBSERVATIONAL RETROSPECTIVE SUBGROUP ANALYSIS OF VERTEPORFIN PHOTODYNAMIC THERAPY-NAIVE AND PREVIOUSLY TREATED PATIENTS IN THE FOCUS TRIAL. [2010.09.18]
Photodynamic therapy with verteporfin in polypoidal choroidal vasculopathy: results after 3 years of follow-up. [2010.09]
Photodynamic therapy with verteporfin for symptomatic circumscribed choroidal hemangioma: five-year outcomes. [2010.08]
[Photodynamic therapy with verteporfin: from neovascularization to hemangioma]. [2010.07]
Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. [2010.06]
Cellular localization of Visudyne as a function of time after local injection in an in vivo model of squamous cell carcinoma: an investigation into tumor cell death. [2010.05]
Verteporfin PDT for non-standard indications--a review of current literature. [2010.05]
Intravitreal bevacizumab alone versus combined verteporfin photodynamic therapy and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration: visual acuity after 1 year of follow-up. [2010.04]
Intravitreal anti-VEGF versus photodynamic therapy with verteporfin for treatment of myopic choroidal neovascularization. [2010.03]
Triple therapy for neovascular age-related macular degeneration (verteporfin photodynamic therapy, intravitreal dexamethasone, and intravitreal bevacizumab). [2010.02]
Verteporfin photodynamic therapy of retinal capillary hemangioblastoma in von Hippel-Lindau disease. [2010.01]
Contact transcleral ciliary body photodynamic therapy with verteporfin in pigmented rabbits: effect of repeated treatments. [2010.01]
Verteporfin PDT for subfoveal occult CNV in AMD: two-year results of a randomized trial. [2009.08]
Factor VII-verteporfin for targeted photodynamic therapy in a rat model of choroidal neovascularization. [2009.08]
[Photodynamic therapy with verteporfin combined with intravitreal injection of ranibizumab for occult and classic CNV in AMD] [2009.06]
Verteporfin photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration. [2009.04]
Observational prospective study of the effectiveness in routine clinical practice of verteporfin photodynamic therapy in patients with neovascular age-related macular degeneration. [2009.04]
Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration. [2009.02]
|
